Geron Corporation (GERN) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal mixed sentiments. While there is positive news about the demand growth for RYTELO and strategic efforts to engage KOLs, the decline in net revenues and lack of specific guidance are concerning. The stable expenses and cash position are neutral factors. The Q&A section shows cautious optimism but also highlights management's reluctance to provide specific data. Given the market cap, the overall impact is likely neutral, with a slight lean towards positive due to the strategic focus and potential demand growth.
Key Financial Performance
Q2 RYTELO net revenues $49 million, representing an increase of approximately 24% over the first quarter. This was driven in part by increased demand from new patient starts.
Quarter-over-quarter demand growth 17% higher compared to the first quarter. This growth was attributed to the execution of the commercial plan of action by the cross-functional team.
Number of sites of care utilizing RYTELO Approximately 1,000 sites, an increase of approximately 400 new sites since the beginning of the year. This growth reflects the expansion of the customer base.
Payer access for RYTELO Approximately 90% of U.S. covered lives now under favorable RYTELO medical coverage policies, an increase from 85% in the first quarter. This improvement is due to strengthened payer access.
Cash and marketable securities as of June 30, 2025 Approximately $433 million, compared to $503 million as of December 31, 2024. The decrease is attributed to operational expenses and investments.
Research and development expenses for Q2 2025 $22 million, compared to $31 million for the same period in 2024. The decrease was primarily due to lower clinical trial costs and manufacturing costs being capitalized after FDA approval of RYTELO.
Selling, general and administrative expenses for Q2 2025 $39 million, roughly unchanged from the same period last year. This stability reflects consistent investment in commercialization and operational activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
RYTELO net revenues: Q2 RYTELO net revenues were $49 million, representing an increase of approximately 24% over the first quarter. This was driven in part by increased demand from new patient starts.
RYTELO commercialization: The company is focused on increasing brand awareness, improving physician prescribing confidence, and expanding KOL support. Efforts include expanding the sales force by over 20%, doubling the size of the medical affairs organization, and implementing community-based educational initiatives.
RYTELO market penetration: Approximately 1,000 sites of care have utilized RYTELO since launch, with 400 new sites added since the beginning of the year. Around 30% of new patient starts were in first and second lines of treatment.
European market expansion: Activities are ongoing to support the launch of RYTELO in select EU markets in 2026. The company is focusing on HTA submissions, EAP programs, and commercial distribution.
Financial position: As of June 30, 2025, the company had $433 million in cash and marketable securities. Operating expenses for fiscal year 2025 are expected to range between $270 million and $285 million.
Clinical trial progress: The IMpactMF Phase III trial in relapsed/refractory myelofibrosis is over 95% enrolled, with completion expected by year-end. Interim analysis is anticipated in the second half of 2026.
Leadership transition: Harout Semerjian was appointed as the new President and CEO, bringing over 30 years of experience in hematology and oncology.
Strategic focus: The company has reset its organizational path over the last two quarters, focusing on RYTELO's commercialization and future success.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Commercialization of RYTELO: Challenges in increasing brand awareness among U.S. hematologists and ensuring comprehensive understanding of RYTELO's prescription guidelines. Disruption expected due to sales force expansion and regional changes.
European Market Strategy: Uncertainty in achieving favorable pricing and reimbursement for RYTELO in select EU markets. Financial discipline required for planned EU4 launch.
IMpactMF Phase III Trial: Dependence on death events for interim and final analysis timelines, with potential delays in trial progress.
Financial Position: Decline in cash and marketable securities from $503 million to $433 million within six months, raising concerns about long-term financial sustainability.
Operational Costs: High operating expenses projected for 2025, ranging from $270 million to $285 million, driven by commercialization and post-marketing commitments.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
RYTELO Commercialization in the U.S.: The company is focused on increasing brand awareness among U.S. hematologists treating lower-risk MDS patients, improving physician confidence in prescribing RYTELO, and expanding KOL support and advocacy. The expanded sales force and medical affairs team are expected to show impact by year-end 2025.
European Market Strategy: Geron plans to launch RYTELO in select EU markets in 2026, pending favorable pricing and reimbursement. The company is focusing on HTA submissions, EAP programs, and commercial distribution in the EU4 countries.
IMpactMF Phase III Trial: The trial is over 95% enrolled, with completion expected by year-end 2025. Interim analysis is anticipated in the second half of 2026, and final analysis in the second half of 2028, based on death event assumptions.
Financial Guidance: Total operating expenses for fiscal year 2025 are expected to range between $270 million and $285 million, including investments in RYTELO commercialization, commercial supply redundancies, and preparations for the EU launch.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How many active patients are now receiving RYTELO, and what percentage of new patients are in the front and second line?
A:The exact number of active patients is not reported due to imperfect data in the buy-and-bill market. However, it is estimated that there are at least 600+ patients based on the 1,000+ accounts prescribing RYTELO, with 2/3 reordering in the previous quarter. Approximately 30% of new patients are in the first and second line.
Q:How sustainable is the 17% quarter-over-quarter demand growth for RYTELO?
A:The sustainability of the 17% growth is supported by business drivers such as new patient starts and duration of treatment. Physicians are increasingly using RYTELO in earlier lines (first and second line), and market research shows high intent to prescribe, indicating positive trends.
Q:What is the company's strategy for engaging Key Opinion Leaders (KOLs)?
A:The company is increasing its KOL engagement through incremental budget allocation for speaker programs, large conferences, peer-to-peer programs, and advisory meetings. They are tailoring engagement to KOLs' interests and needs, collecting insights for clinical development, and enhancing awareness in the medical community.
Q:What were the biggest issues holding back the launch in 4Q and 1Q, and what strategies were employed in 2Q to address them?
A:The main issues were lack of awareness, comfort, and clarity in prescribing, and insufficient KOL engagement. Strategies in 2Q included increasing product awareness, ensuring prescribing clarity, and engaging KOLs for advocacy. These efforts led to encouraging results and are expected to drive long-term growth.
Q:What is the visibility on the duration of therapy for RYTELO?
A:The company uses market research, specialty pharmacy data, and patient chart audits to assess duration. In the IMerge trial, the duration of treatment was 7.8 months. Currently, most patients are in third line or later, where duration tends to be shorter. As usage shifts to earlier lines, duration is expected to increase.
Q:What are the early 3Q demand trends for RYTELO?
A:The company observes cautious optimism for continued demand growth based on internal sales data and syndicated claims data, focusing on rolling averages to track trends.
Q:What is the status of enrollment for the myelofibrosis study?
A:Enrollment is progressing well, with no further obstacles. Initial challenges like high screen failure rates have decreased, and the study is expected to complete enrollment by year-end.
Q:What type of physicians are prescribing RYTELO in earlier lines?
A:Both community and academic physicians are prescribing RYTELO. Physicians who have had success with the drug in later lines are more likely to use it in earlier lines. Awareness and experience with the drug's efficacy and safety are driving increased prescriptions.
Q:What are the reasons for patient discontinuation of RYTELO?
A:Market research suggests that cytopenias are a common reason for discontinuation. The company is focusing on educating physicians and generating data to improve patient outcomes and retention.
Q:What is the company's expectation for first-line and second-line usage of RYTELO?
A:The company aims for appropriate use in first-line ESA ineligible patients and ESA relapsed/refractory patients in second line or later. They believe RYTELO is highly differentiated and are working to increase awareness and understanding of its product profile.
Q:What is the EU commercialization strategy for RYTELO?
A:The priority is to secure the highest possible reimbursable rate, which involves country-by-country negotiations. The company is maintaining financial discipline and engaging with a partner to potentially commercialize in the EU4 and other regions, contingent on favorable reimbursement.
Q:What metrics are being used to assess the recalibration of the sales team?
A:Metrics include sales performance at regional and territory levels, execution metrics like reach and frequency, and calls on top targets and physicians.
Q:Review of Unclear Management Responses
A:Management avoided providing specific data on the exact number of active patients receiving RYTELO, the split between first-line and second-line usage, and early 3Q demand trends. They also did not provide detailed reasons for patient discontinuation beyond cytopenias or specific metrics for recalibrating the sales team. Additionally, they did not disclose the timing of a potential EU commercialization agreement or specific attributes of the partner they are engaging with.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Annual
Bir Interim
Borah
Corporate Participant
Directors
Executive VP
HCP
III trial
KOL support
LLC Research
Phase III
President CEO
President Research
QA
Research Development
Research Division
Semerjian
Slide
advocacy
affair
appointment
awareness
commercialization
death event
demand patient
enrollment end
field team
inventory week
leader
plan action
presence
priority KOL
reach
success
support RYTELO
transition
use
GERN Transcript
Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call presents a mixed outlook. While there is positive revenue growth and a slight improvement in net loss, uncertainties in financial resources and commercialization challenges are highlighted. The market expansion for RYTELO in the U.S. and EU is promising, but risks and increased expenses temper enthusiasm. The lack of shareholder return discussion and the absence of clear management responses in the Q&A further contribute to a neutral sentiment. Given the market cap, the stock price is likely to remain stable within a -2% to 2% range over the next two weeks.
Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
GERN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
